NCT05567055View on ClinicalTrials.gov

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

October 3, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2028

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Capmatinib

Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR